Weaver C. Barksdale & Associates, Inc. / BMY
Weaver C. Barksdale & Associates, Inc.’s Bristol-Myers Squibb Co Position
Does Weaver C. Barksdale & Associates, Inc. own Bristol-Myers Squibb Co (BMY)? Yes — 18.8K shares worth $1M (+1.08% of its 13F portfolio) as of Q1 2026, down from 19.4K shares the prior filed quarter.
Position Value
$1M
Q1 2026
Shares
18.8K
% of Portfolio
+1.08%
Quarters Held
18
currently held
Position History BMY
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 18.8K | $1M | +1.08% |
| Q4 2025 | 19.4K | $1M | +1.10% |
| Q3 2025 | 23.2K | $1M | +1.01% |
| Q2 2025 | 25.4K | $1M | +1.12% |
| Q1 2025 | 25.6K | $2M | +1.50% |
| Q4 2024 | 26.5K | $1M | +1.44% |
| Q3 2024 | 19.6K | $1M | +0.91% |
| Q2 2024 | 20.6K | $856,267 | +0.81% |
| Q1 2024 | 21.1K | $1M | +1.05% |
| Q4 2023 | 21.4K | $1M | +1.07% |
| Q3 2023 | 28.7K | $2M | +1.42% |
| Q2 2023 | 24.5K | $2M | +1.55% |
| Q1 2023 | 26.2K | $2M | +1.70% |
| Q4 2022 | 23.0K | $2M | +1.46% |
| Q3 2022 | 22.3K | $2M | +1.59% |
| Q2 2022 | 23.2K | $2M | +1.66% |
| Q1 2022 | 23.0K | $2M | +1.49% |
| Q4 2021 | 22.6K | $1M | +1.28% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Weaver C. Barksdale & Associates, Inc.’s full portfolio or all institutional holders of BMY.